22nd Century Group Stock News

22nd Century and Aurora Cannabis made an agreement with Cronos Group to license their cannabinoid biosynthesis intellectual property.

Canadian marijuana titan Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:ACB) together with 22nd Century Group, Inc. (NASDAQ: XXII) will license biosynthesis intellectual property to Cronos Group Inc. (NASDAQ

Canadian marijuana titan Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) together with 22nd Century Group, Inc. (NASDAQ:XXII) will license biosynthesis intellectual property to Cronos Group Inc. (NASDAQ:C

The trading price of 22nd Century Group Inc. (NASDAQ:XXII) closed lower on Monday, December 13, closing at $2.27, -1.30% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Campbell Wealth Management bought a new position in shares of 22nd Century Group, Inc. (NYSEAMERICAN:XXII) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 15,000 shares of the biotechnology companys stock, valued at approximately $44,000. Other hedge funds also recently made []

BUFFALO, N.Y., Dec. 10, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through plant science, announced today that it is fully engaged and ready to provide commercial support to the New Zealand Ministry of Healths Smokefree Aotearoa 2025 Action Plan, including supplying reduced nicotine content combustible cigarettes able to meet New Zealands proposed standards.

The Best Daily Overview Of The Cannabis Space Valens Co. Commences Trading on NASDAQ under symbol $VLNS Public companies discussed in today's episode: Valens Co Inc COM NEW (NASDAQ: VLNS)

Valens Co. Commences Trading on NASDAQ under symbol $VLNS Public companies discussed in today's episode:

In the last trading session, 1.61 million 22nd Century Group Inc. (NASDAQ:XXII) shares changed hands as the companys beta touched 1.88. With the companys per share price at $2.33 changed hands at -$0.15 or -6.05% during last session, the market valuation stood at $403.60M. XXIIs last price was a discount, traded about -160.52% off its 22nd Century Group Inc. (NASDAQ: XXII): The Most Interesting Shares Today Read More »

During the recent session, 22nd Century Group Inc. (NASDAQ:XXII)s traded shares were 1.21 million, with the beta value of the company hitting 1.86. At the last check today, the stocks price was $2.55, reflecting an intraday loss of -8.27% or -$0.23. The 52-week high for the XXII share is $6.07, that puts it down -138.04 How Could You Make A Quick Recovery From 22nd Century Group Inc. (NASDAQ: XXII) Given A -96.08% Drop From Highs? Read More »

Leafly Hires Rebecca Warner As VP Of Sales The cannabis information platform Leafly Holdings, Inc. said Wednesday that it has hired Rebecca Warner to serve as senior vice president of sales. In her n

The trading price of 22nd Century Group Inc. (NASDAQ:XXII) closed lower on Monday, November 22, closing at $2.82, -1.40% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

BUFFALO, N.Y., Nov. 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced today that Richard Fitzgerald has joined the Company as its Chief Financial Officer, effective November 15, 2021. John Franzino, the Companys previous Chief Financial Officer, has transitioned to Chief Administrative Officer, where he will be responsible for further developing the company''s business processes and leading the Companys financial planning and analysis, operational finance, human resources, and information technology functions.

22nd Century Group Inc. (NASDAQ:XXII) price closed higher on Monday, November 15, jumping 8.05% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

BUFFALO, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through plant science, announced today that it strongly supports the nomination of Dr. Robert Califf as the next commissioner of the U.S. Food and Drug Administration (FDA). Califf is known to be a longtime proponent of tobacco control and supporter of the Agency’s Comprehensive Plan for Tobacco and Nicotine Regulation .